2. High-Risk Arena (ARNA) At Friday's $6.62/share close, going into its FDA decision for Lorcaserin on 27 June, short-term traders could jump in and jump out for a modest $7-8/share target. But this is a high-risk situation. If bad news comes (perish the thought!), the stock could plummet to $2 in a heart-beat. On great news, I perceive $10/share as the lowest minimum upside. Should it be approved as the first weight loss drug in a long time, it wouldn't surprise me to see market sentiment drive it to $30/share or higher. Valuation aside, market sentiment plays a big role here. Stocks rarely trade on the metrics of value alone; they also trade on market sentiment. If Lorcaserin is approved, look out.
All material posted by langlui is purely my opinion and is not buy or sell recommendations. Do your DD, buy and sell based on that DD.